Loading stock data…
CPIX
$5.72-0.14 (-2.39%)
After Hours$5.72+0.00 (+0.00%)· Last close Jun 9
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cumberland Pharmaceuticals Inc. in the Healthcare sector is trading at $5.72 with a market capitalization of $84M. The stock is currently near its 52-week high of $6.61, remaining 57.1% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$5.72
Potential Downside
0%
Whystock Fair Value$5.72
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Cal...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$84.06M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.06
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-34.12%
Volume
Today's trading volume
52,466
Recent News
Cumberland Expands Global Reach With Vibativ Launch in China
CPIX launches Vibativ in China through SciClone, expanding access to its antibiotic treatment for serious Gram-positive bacterial infections.
The Zacks Analyst Blog Highlights Alphabet, Apple, Micron Technology, Cumberland Pharmaceuticals and AmeriServ Financial
Alphabet, Apple and Micron lead Zacks analyst reports as AI demand and product cycles drive tech momentum.
Top Analyst Reports for Alphabet, Apple & Micron Technology
Alphabet's AI-driven growth in Search, Cloud and subscriptions is boosting momentum, though spending and legal risks remain in focus.
Cumberland Posts Loss in Q1 Amid $100M Apotex Deal Plan
CPIX posts a wider y//y loss in Q1, as it unveils a $100-million Apotex deal and sharpens focus on orphan drug development.
Cumberland Pharmaceuticals Inc. Q1 2026 Earnings Call Summary
Moby summary of Cumberland Pharmaceuticals Inc.'s Q1 2026 earnings call